Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance

References

• Ho J, Tambyah PA, Paterson DL. Multiresistant Gram-negative infections: a global perspective. Curr Opin Infect Dis. 2010;23(6):546–553.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Matthaiou DK, et al. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents. 2008;32(5):450–454.
   PubMed Web of Science ®Google Scholar
• Chen LF, Chopra T, Kaye KS. Pathogens resistant to antibacterial agents. Infect Dis Clin North Am. 2009;23(4):817–845, vii.
   PubMed Web of Science ®Google Scholar
• Rice LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol. 2009;12(5):476–481.
   PubMed Web of Science ®Google Scholar
• Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther. 2008;6(5):751–763.
   PubMed Web of Science ®Google Scholar
• Kollef KE, Schramm GE, Wills AR, et al. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest. 2008;134(2):281–287.
   PubMed Web of Science ®Google Scholar
• Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;136(5):1237–1248.
   PubMed Web of Science ®Google Scholar
• de Kraker ME, Wolkewitz M, Davey PG, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother. 2011;66(2):398–407.
   PubMed Web of Science ®Google Scholar
• Alsan M, Schoemaker L, Eggleston K, et al. Out-of-pocket health expenditures and antimicrobial resistance in low-income and middle-income countries: an economic analysis. Lancet Infect Dis. 2015;15(10):1203–1210.
   PubMed Web of Science ®Google Scholar
• MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. J Hosp Med. 2014;9(4):232–238.
   PubMed Web of Science ®Google Scholar
• Leistner R, Gurntke S, Sakellariou C, et al. Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort. Infection. 2014;42(6):991–997.
   PubMed Web of Science ®Google Scholar
• Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(Suppl 2):S82–89.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.
   PubMed Web of Science ®Google Scholar
• Peterson LR. Bad bugs, no drugs: no ESCAPE revisited. Clin Infect Dis. 2009;49(6):992–993.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Powers JH, Brass EP, et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004;38(9):1279–1286.
   PubMed Web of Science ®Google Scholar
• Spratt BG, Cromie KD. Penicillin-binding proteins of gram-negative bacteria. Rev Infect Dis. 1988;10(4):699–711.
   PubMedGoogle Scholar
• Ambler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980;289(1036):321–331.
   PubMed Web of Science ®Google Scholar
• MacGowan A. Revisiting beta-lactams - PK/PD improves dosing of old antibiotics. Curr Opin Pharmacol. 2011;11(5):470–476.
   PubMed Web of Science ®Google Scholar
• Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27(1):10–22.
   PubMed Web of Science ®Google Scholar
• Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am. 2009;23(4):791–815, vii.
   PubMed Web of Science ®Google Scholar
• Ruppe E, Woerther PL, Barbier F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care. 2015;5(1):61.
   PubMed Web of Science ®Google Scholar
• Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011;86(3):250–259.
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Flamm RK, et al. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis. 2014;78(4):443–448.
   PubMed Web of Science ®Google Scholar
• Prabaker K, Weinstein RA. Trends in antimicrobial resistance in intensive care units in the United States. Curr Opin Crit Care. 2011;17(5):472–479.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. Jama. 2009;302(21):2323–2329.
   PubMed Web of Science ®Google Scholar
• Zilahi G, Artigas A, Martin-Loeches I. What’s new in multidrug-resistant pathogens in the ICU? Ann Intensive Care. 2016;6(1):96.
   PubMed Web of Science ®Google Scholar
• Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1–14.
   PubMed Web of Science ®Google Scholar
• Centers for Disease C. Prevention. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep. 2013;62(9):165–170.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Lomaestro BM, Drusano GL. Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006;26(9):1320–1332.
   PubMed Web of Science ®Google Scholar
• Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother. 2005;49(1):461–463.
   PubMed Web of Science ®Google Scholar
• Mouton JW, Den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994;38(5):931–936.
   PubMed Web of Science ®Google Scholar
• Alou L, Aguilar L, Sevillano D, et al. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J Antimicrob Chemother. 2005;55(2):209–213.
   PubMed Web of Science ®Google Scholar
• Kaufman SE, Donnell RW, Hickey WS. Rationale and evidence for extended infusion of piperacillin-tazobactam. Am J Health Syst Pharm. 2011;68(16):1521–1526.
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1-10; quiz 11-12.
   Web of Science ®Google Scholar
• Baudel JL, Tankovic J, Carrat F, et al. Does nonadherence to local recommendations for empirical antibiotic therapy on admission to the intensive care unit have an impact on in-hospital mortality? Ther Clin Risk Manag. 2009;5(3):491–498.
   PubMedGoogle Scholar
• Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38(4):1045–1053.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072–1083.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet. 2006;45(8):755–773.
   PubMed Web of Science ®Google Scholar
• Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013;56(2):236–244.
   PubMed Web of Science ®Google Scholar
• Wong G, Briscoe S, Adnan S, et al. Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother. 2013;57(12):6165–6170.
   PubMed Web of Science ®Google Scholar
• Sime FB, Roberts MS, Peake SL, et al. Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care. 2012;2(1):35.
   PubMed Web of Science ®Google Scholar
• Roberts JA, De Waele JJ, Dimopoulos G, et al. DALI: defining antibiotic levels in intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infect Dis. 2012;12:152.
   PubMed Web of Science ®Google Scholar
• De Waele JJ, Lipman J, Akova M, et al. Risk factors for target non-attainment during empirical treatment with beta-lactam antibiotics in critically ill patients. Intensive Care Med. 2014;40(9):1340–1351.
   PubMed Web of Science ®Google Scholar
• Bauer KA, West JE, O’Brien JM, et al. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2013;57(7):2907–2912.
   PubMed Web of Science ®Google Scholar
• Lorente L, Lorenzo L, Martin MM, et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother. 2006;40(2):219–223.
   PubMed Web of Science ®Google Scholar
• Kasiakou SK, Sermaides GJ, Michalopoulos A, et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis. 2005;5(9):581–589.
   PubMed Web of Science ®Google Scholar
• Teo J, Liew Y, Lee W, et al. Prolonged infusion versus intermittent boluses of beta-lactam antibiotics for treatment of acute infections: a meta-analysis. Int J Antimicrob Agents. 2014;43(5):403–411.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med. 2009;37(6):2071–2078.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Putcha N, Suh YD, et al. Does prolonged beta-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. BMC Infect Dis. 2011;11:181.
   PubMed Web of Science ®Google Scholar
• De Waele J, Carlier M, Hoste E, et al. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis. Minerva Anestesiol. 2014;80(12):1302–1309.
   PubMed Web of Science ®Google Scholar
• Lodise TP Jr., Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44(3):357–363.
   PubMed Web of Science ®Google Scholar
• Yost RJ, Cappelletty DM; group RS. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study. Pharmacotherapy. 2011;31(8):767–775.
   PubMed Web of Science ®Google Scholar
• Cutro SR, Holzman R, Dubrovskaya Y, et al. Extended-infusion versus standard-infusion piperacillin-tazobactam for sepsis syndromes at a tertiary medical center. Antimicrob Agents Chemother. 2014;58(8):4470–4475.
   PubMed Web of Science ®Google Scholar
• Schmees PM, Bergman SJ, Strader BD, et al. Outcomes of an extended-infusion piperacillin-tazobactam protocol implementation in a community teaching hospital adult intensive care unit. Am J Health Syst Pharm. 2016;73(11 Suppl 3):S100–105.
   PubMed Web of Science ®Google Scholar
• Nicasio AM, Eagye KJ, Nicolau DP, et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care. 2010;25(1):69–77.
   PubMed Web of Science ®Google Scholar
• Rafati MR, Rouini MR, Mojtahedzadeh M, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents. 2006;28(2):122–127.
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016;42(10):1535–1545.
   PubMed Web of Science ®Google Scholar
• Wang Z, Shan T, Liu Y, et al. [Comparison of 3-hour and 30-minute infusion regimens for meropenem in patients with hospital acquired pneumonia in intensive care unit: a randomized controlled clinical trial]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014;26(9):644–649.
   PubMedGoogle Scholar
• Fan SY, Shum HP, Cheng WY, et al. clinical outcomes of extended versus intermittent infusion of piperacillin/tazobactam in critically ill patients: a prospective clinical trial. Pharmacotherapy. 2017;37(1):109–119.
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Lipman J, Akova M, et al. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. J Antimicrob Chemother. 2016;71(1):196–207.
   PubMed Web of Science ®Google Scholar
• Chytra I, Stepan M, Benes J, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care. 2012;16(3):R113.
   PubMed Web of Science ®Google Scholar
• Dulhunty JM, Roberts JA, Davis JS, et al. A multicenter randomized trial of continuous versus intermittent beta-lactam infusion in severe sepsis. Am J Respir Crit Care Med. 2015;192(11):1298–1305.
   PubMed Web of Science ®Google Scholar
• Yusuf E, Spapen H, Pierard D. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review. J Crit Care. 2014;29(6):1089–1095.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Davis JS, et al. Continuous versus intermittent beta-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194(6):681–691.
   PubMed Web of Science ®Google Scholar
• Claus B, Buyle F, Robays H, et al. Importance of infusion volume and pump characteristics in extended administration of ss-lactam antibiotics. Antimicrob Agents Chemother. 2010;54(11):4950.
   PubMed Web of Science ®Google Scholar
• Carlier M, Stove V, Verstraete AG, et al. Stability of generic brands of meropenem reconstituted in isotonic saline. Minerva Anestesiol. 2015;81(3):283–287.
   PubMed Web of Science ®Google Scholar
• Berthoin K, Le Duff CS, Marchand-Brynaert J, et al. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother. 2010;65(5):1073–1075.
   PubMed Web of Science ®Google Scholar
• Adam S, Bianca G, Krispin H, et al. The use of therapeutic drug monitoring to optimize treatment of carbapenem resistant enterobacter osteomyelitis. Microb Drug Resist. 2015 December;21(6):631–635.
   PubMed Web of Science ®Google Scholar